Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus

Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.70, $0.50 better than the analyst estimate of $1.20. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.01 billion.

"In 2019, our differentiated strategy of investing in serial scientific innovation to create transformative medicines delivered remarkable performance. This was marked by the early approval of TRIKAFTA, the rapid progression of our pipeline in additional diseases and continued financial growth as we continued to treat more patients with our medicines worldwide," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "This success is the culmination of many years of hard work to build a team, a pipeline and a company that we believe will discover, develop and commercialize transformative medicines for years to come."

GUIDANCE:

Vertex Pharma sees FY2020 revenue of $5.1-5.3 billion, versus the consensus of $4.87 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Wealthfront launches custodial account with tax-gain harvesting
• U.S. Bank hires Eric Levine to head healthcare payments unit